GLOW Blend Research Peptides

The UK listings reviewed most commonly describe GLOW as BPC-157 + TB-500 + GHK-Cu. Several use 10 mg BPC-157, 10 mg TB-500 and 50 mg GHK-Cu, but GLOW is a commercial name rather than a standardised formulation, so each product must be checked individually. [S18] [S19] [S20] [S22]

No primary human, animal or laboratory study of the exact BPC-157 + TB-500 + GHK-Cu three-component mixture was located in the targeted searches for this review. That means direct blend efficacy, synergy and safety remain unestablished. [S12] [S13]

Yes. A 2026 rat Achilles-tendon study directly tested them separately and together. The authors reported that the combination did not confer additional benefit over either agent alone. [S3]

No. Analytical research identified marketed TB-500 as the N-acetylated seven-residue fragment Ac-LKKTETQ, while full-length thymosin beta-4 is a different 43-residue molecule. Supplier labels still need verification because terminology is inconsistent. [S4] [S5] [S6]

No. GHK is the copper-free tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is a copper complex of that peptide. Evidence and analytical identity should distinguish the two. [S7] [S8]

No. Some human topical GHK-Cu studies report wound or skin findings, while another small randomized post-laser study found no objective advantage on several skin outcomes. Those topical results do not establish the effect of a three-component research blend. [S9] [S10] [S11]

No. No direct three-component synergy study was located. The closest pair study, BPC-157 plus TB-500 in rats, did not show additional benefit from combining the two in the authors' conclusion. [S3] [S12] [S13]

No. The total is the combined labelled mass. Where a supplier states 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, those three amounts sum to 70 mg total. Never treat the total as the amount of each component. [S18] [S19] [S20]

No. The commercial name does not define a ratio. A 60 mg GLOW-labelled listing was observed without a verified component breakdown, while several UK 70 mg listings state 50/10/10 mg. Product-level quantities must be recorded from the actual label or report. [S18] [S19] [S20] [S22]

In the UK listings reviewed, GLOW contains BPC-157, TB-500 and GHK-Cu, while KLOW adds KPV as a fourth component. These are commercial naming conventions rather than scientific formulation standards. [S20] [S21]

Not necessarily. A useful blend report must show what analytes were tested and whether each component was identified and, where claimed, quantified. A single purity percentage does not establish the identity and amount of all three ingredients, sterility or human-use suitability. [S14] [S18] [S19] [S20]

Targeted MHRA product-information searches did not locate a UK-authorised GLOW medicinal product as of 22 September 2026. That search finding should not be expanded into a blanket legal conclusion about every research transaction or unlicensed-medicine pathway. [S16] [S17]

The blend name itself is not needed for the anti-doping analysis. BPC-157 is prohibited under WADA S0, and thymosin-β4 and its derivatives including TB-500 are prohibited under S2.3. Athletes should not infer that other components are permitted merely because they are not named here. [S15]